These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 3279496

  • 1. Quinolones in the treatment of serious infections.
    Webster A, Gaya H.
    Rev Infect Dis; 1988; 10 Suppl 1():S225-33. PubMed ID: 3279496
    [Abstract] [Full Text] [Related]

  • 2. Clinical use of the quinolones.
    Neu HC.
    Lancet; 1987 Dec 05; 2(8571):1319-22. PubMed ID: 2890913
    [No Abstract] [Full Text] [Related]

  • 3. Clinical uses of nalidixic acid analogues: the fluoroquinolones.
    Høiby N.
    Eur J Clin Microbiol; 1986 Apr 05; 5(2):138-40. PubMed ID: 3013628
    [No Abstract] [Full Text] [Related]

  • 4. Quinolones in the treatment of bronchopulmonary infections.
    Thys JP.
    Rev Infect Dis; 1988 Apr 05; 10 Suppl 1():S212-7. PubMed ID: 3279495
    [Abstract] [Full Text] [Related]

  • 5. Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
    Maesen FP, Davies BI, Teengs JP, Baur C.
    Eur J Respir Dis Suppl; 1986 Apr 05; 146():585-90. PubMed ID: 3465584
    [No Abstract] [Full Text] [Related]

  • 6. Quinolones.
    Shah PM.
    Prog Drug Res; 1987 Apr 05; 31():243-56. PubMed ID: 3326031
    [No Abstract] [Full Text] [Related]

  • 7. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG, Sörgel F, Gutzler F, Bartosik-Wich B.
    Infection; 1985 Apr 05; 13(5):219-24. PubMed ID: 2933340
    [Abstract] [Full Text] [Related]

  • 8. [Fluoroquinolones].
    Baykal M, Akalin E.
    Mikrobiyol Bul; 1987 Apr 05; 21(2):151-7. PubMed ID: 3482120
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R, Griggs D, Andrews JM.
    Rev Infect Dis; 1988 Apr 05; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [Abstract] [Full Text] [Related]

  • 10. [New oral quinolone compounds in chronic bronchitis].
    Davies BI, Maesen FP, Teengs JP, Baur C.
    Infection; 1986 Apr 05; 14 Suppl 1():S73-8. PubMed ID: 2937739
    [Abstract] [Full Text] [Related]

  • 11. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL.
    Drugs; 1987 Apr 05; 34 Suppl 1():159-69. PubMed ID: 3481317
    [Abstract] [Full Text] [Related]

  • 12. [Therapeutic contribution of the new quinolones].
    Wolff M.
    Rev Prat; 1987 Apr 11; 37(21):1209-14. PubMed ID: 3474759
    [No Abstract] [Full Text] [Related]

  • 13. Comparative pharmacokinetics of new quinolones.
    Lode H, Höffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P, Sievers B, Reimnitz D, Borner K, Koeppe P.
    Drugs; 1987 Apr 11; 34 Suppl 1():21-5. PubMed ID: 3481323
    [Abstract] [Full Text] [Related]

  • 14. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P.
    Infection; 1986 Apr 11; 14(3):142-4. PubMed ID: 2942489
    [Abstract] [Full Text] [Related]

  • 15. Review of the 4-quinolones.
    Eggleston M, Park SY.
    Infect Control; 1987 Mar 11; 8(3):119-25. PubMed ID: 3553053
    [Abstract] [Full Text] [Related]

  • 16. The comparative pharmacokinetics of five quinolones.
    Wise R, Lister D, McNulty CA, Griggs D, Andrews JM.
    J Antimicrob Chemother; 1986 Nov 11; 18 Suppl D():71-81. PubMed ID: 3468102
    [Abstract] [Full Text] [Related]

  • 17. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H, Quentin C, de Barbeyrac B, Bebear C.
    Pathol Biol (Paris); 1988 May 11; 36(5):496-9. PubMed ID: 3136430
    [Abstract] [Full Text] [Related]

  • 18. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
    Hooper DC, Wolfson JS.
    Antimicrob Agents Chemother; 1985 Nov 11; 28(5):716-21. PubMed ID: 2936302
    [No Abstract] [Full Text] [Related]

  • 19. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C, Nord CE.
    Scand J Infect Dis; 1986 Nov 11; 18(2):149-51. PubMed ID: 2939556
    [Abstract] [Full Text] [Related]

  • 20. New quinolones in the treatment of joint and bone infections.
    Desplaces N, Acar JF.
    Rev Infect Dis; 1988 Nov 11; 10 Suppl 1():S179-83. PubMed ID: 3279491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.